A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
This randomized phase III trial compares nivolumab with ipilimumab and nivolumab alone in
treating patients with stage IV squamous cell lung cancer that has come back after previous
treatment. This is a "non-match" sub-study that includes all screened patients not eligible
for a biomarker-driven sub-study. Monoclonal antibodies, such as nivolumab and ipilimumab,
may be able to shrink tumours. It is not yet known whether nivolumab works better with or
without ipilimumab in treating patients with squamous cell lung cancer.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society